167 related articles for article (PubMed ID: 17346346)
1. Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services.
Strauss SM; Astone-Twerell J; Munoz-Plaza CE; Des Jarlais DC; Gwadz M; Hagan H; Osborne A; Rosenblum A
BMC Health Serv Res; 2007 Mar; 7():39. PubMed ID: 17346346
[TBL] [Abstract][Full Text] [Related]
2. Injection drug users and the provision of hepatitis C-related services in a nationwide sample of drug treatment programs.
Vassilev ZP; Strauss SM; Astone J; Des Jarlais DC
J Behav Health Serv Res; 2004; 31(2):208-16. PubMed ID: 15255228
[TBL] [Abstract][Full Text] [Related]
3. Using latent class analysis to identify patterns of hepatitis C service provision in drug-free treatment programs in the U.S.
Strauss SM; Rindskopf DM; Astone-Twerell JM; Des Jarlais DC; Hagan H
Drug Alcohol Depend; 2006 Jun; 83(1):15-24. PubMed ID: 16289523
[TBL] [Abstract][Full Text] [Related]
4. Outpatient drug treatment program directors' hepatitis C-related beliefs and their relationship to the provision of HCV services.
Astone JM; Strauss SM; Hagan H; Des Jarlais DC
Am J Drug Alcohol Abuse; 2004 Nov; 30(4):783-97. PubMed ID: 15624549
[TBL] [Abstract][Full Text] [Related]
5. Provision of hepatitis C education in a nationwide sample of drug treatment programs.
Astone J; Strauss SM; Vassilev ZP; Des Jarlais DC
J Drug Educ; 2003; 33(1):107-17. PubMed ID: 12773028
[TBL] [Abstract][Full Text] [Related]
6. Staff perspectives on facilitating the implementation of hepatitis C services at drug treatment programs.
Munoz-Plaza CE; Strauss SM; Astone-Twerwll JM; Des Jarlais DC; Hagan H
J Psychoactive Drugs; 2006 Sep; 38(3):233-41. PubMed ID: 17165366
[TBL] [Abstract][Full Text] [Related]
7. HIV infection and risk, prevention, and testing behaviors among injecting drug users -- National HIV Behavioral Surveillance System, 20 U.S. cities, 2009.
Broz D; Wejnert C; Pham HT; DiNenno E; Heffelfinger JD; Cribbin M; Krishna N; Teshale EH; Paz-Bailey G;
MMWR Surveill Summ; 2014 Jul; 63(6):1-51. PubMed ID: 24990587
[TBL] [Abstract][Full Text] [Related]
8. The content and comprehensiveness of hepatitis C education in methadone maintenance and drug-free treatment units.
Strauss SM; Astone JM; Hagan H; Des Jarlais DC
J Urban Health; 2004 Mar; 81(1):38-47. PubMed ID: 15047782
[TBL] [Abstract][Full Text] [Related]
9. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C knowledge among staff in U.S. drug treatment programs.
Strauss SM; Astone-Twerell JM; Munoz-Plaza C; Des Jarlais DC; Gwadz M; Hagan H; Osborne A; Rosenblum A
J Drug Educ; 2006; 36(2):141-58. PubMed ID: 17153514
[TBL] [Abstract][Full Text] [Related]
11. "It gives me a sense of belonging": providing integrated health care and treatment to people with HCV engaged in a psycho-educational support group.
Woolhouse S; Cooper E; Pickard A
Int J Drug Policy; 2013 Nov; 24(6):550-7. PubMed ID: 23860471
[TBL] [Abstract][Full Text] [Related]
12. Integrating hepatitis C services into existing HIV services: the experiences of a sample of U.S. drug treatment units.
Strauss SM; Astone JM; Des Jarlais DC; Hagan H
AIDS Patient Care STDS; 2005 Feb; 19(2):78-88. PubMed ID: 15716639
[TBL] [Abstract][Full Text] [Related]
13. A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States.
Strauss SM; Astone JM; Jarlais DD; Hagan H
Drug Alcohol Depend; 2004 Mar; 73(3):227-36. PubMed ID: 15036545
[TBL] [Abstract][Full Text] [Related]
14. Barriers to enrollment in drug abuse treatment and suggestions for reducing them: opinions of drug injecting street outreach clients and other system stakeholders.
Appel PW; Ellison AA; Jansky HK; Oldak R
Am J Drug Alcohol Abuse; 2004; 30(1):129-53. PubMed ID: 15083558
[TBL] [Abstract][Full Text] [Related]
15. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection.
Grebely J; Genoway K; Khara M; Duncan F; Viljoen M; Elliott D; Raffa JD; DeVlaming S; Conway B
Int J Drug Policy; 2007 Oct; 18(5):437-43. PubMed ID: 17854734
[TBL] [Abstract][Full Text] [Related]
16. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs.
Treloar C; Hull P; Dore GJ; Grebely J
Drug Alcohol Rev; 2012 Nov; 31(7):918-24. PubMed ID: 22612899
[TBL] [Abstract][Full Text] [Related]
17. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.
Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A;
Int J Drug Policy; 2015 Oct; 26(10):999-1006. PubMed ID: 26275578
[TBL] [Abstract][Full Text] [Related]
18. Knowledge of and interest in hepatitis C treatment at a methadone clinic.
Walley AY; White MC; Kushel MB; Song YS; Tulsky JP
J Subst Abuse Treat; 2005 Mar; 28(2):181-7. PubMed ID: 15780548
[TBL] [Abstract][Full Text] [Related]
19. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia.
Doab A; Treloar C; Dore GJ
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S313-20. PubMed ID: 15768340
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States.
Bini EJ; Kritz S; Brown LS; Robinson J; Calsyn D; Alderson D; Tracy K; McAuliffe P; Smith C; Rotrosen J
J Subst Abuse Treat; 2012 Jun; 42(4):438-45. PubMed ID: 22035702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
